Mobile

A PROSPECTIVE, OPEN-LABEL, NON-RANDOMIZED, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF VORICONAZOLE AS PRIMARY THERAPY FOR TREATMENT OF INVASIVE ASPERGILLOSIS AND MOLDS SUCH AS SC...

Update Il y a 4 ans
Reference: EUCTR2008-005275-10

A PROSPECTIVE, OPEN-LABEL, NON-RANDOMIZED, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF VORICONAZOLE AS PRIMARY THERAPY FOR TREATMENT OF INVASIVE ASPERGILLOSIS AND MOLDS SUCH AS SCEDOSPORIUM OR FUSARIUM SPECIES IN PEDIATRIC PATIENTS

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the safety and tolerability of voriconazole as primary treatment of invasive aspergillosis and rare molds such as Scedosporium or Fusarium species in immunocompromised pediatric subjects from 2 to <18 years of age.

Inclusion criteria

  • Treatment of proven or probable invasive aspergillosis (IA) and rare molds such as Scedosporium or Fusarium species

Links